Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novozymes Biopharma, a part of Novozymes, a company into bioinnovation, is offering its Bacillus-based sodium hyaluronate as a free evaluation sample.
Subscribe to our email newsletter
Novozymes Biopharma claimed that its sodium hyaluronate was awarded the CPhI Gold Innovation Award for its production process allowing for better safety and improved consistency.
Following this sample program Novozymes Biopharma is expected to launch its new cGMP facility in Tianjin, China in 2011.
Novozymes Biopharma’s new facility is expected to provide an opportunity to experience the quality of the product that will be manufactured at the cGMP Q7 validated site.
Novozymes Biopharma said that its sodium hyaluronate is fermented using a non-pathogenic and well documented production strain, Bacillus subtilis, offering the pharmaceutical and medical device industries benefits including increased safety, purity, batch-to-batch consistency and stability in large scale.
Novozymes Biopharma’s sodium hyaluronate can be used in the pharmaceutical sector for improved drug delivery as well as in medical device application areas.
Hans Ole Klingenberg, product director at Novozymes Biopharma, said: “We are delighted to offer new and existing users the opportunity to pilot Novozymes Biopharma’s sodium hyaluronate. We are developing our new cGMP facility in China to expand the use of sodium hyaluronate. This sample program precedes the opening of our new facility.”